James F. List, M.D., Ph.D., is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for improving cardiovascular and diabetes care and disease interception. Jim has end-to-end research and development responsibility for the Janssen CVM portfolio, including drug discovery, clinical development, and external innovation. Jim joined Janssen in 2014.
Prior to joining Janssen, James served with Bristol-Myers Squibb as Vice President, Diabetes Development, with responsibility for the diabetes joint venture alliance with AstraZeneca.
Earlier in his career, James was a faculty member of the Harvard Medical School in Boston, Massachusetts,with clinical responsibilities in General Endocrinology and Thyroid. He graduated from Stanford University in Stanford, California, and completed his M.D. and Ph.D. from the University of Minnesota in Minneapolis, Minnesota. He completed his medical training at Brigham and Women’s Hospital, Boston Children’s Hospital and the Massachusetts General Hospital, all in Boston, Massachusetts, and is board certified in Internal Medicine, Pediatrics and Endocrinology.